"name","text","uuid:ID","instanceType","id","description","label"
"OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","9fd8a3ed-19b3-4844-aa9c-895c294d0206","Objective","Objective_1","Main objective",""
"OBJ2","To document the safety profile of the xanomeline TTS.","54732177-4efa-453a-9384-e3b810dbbcf8","Objective","Objective_2","Safety",""
"OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","0c9f75f4-8c19-468f-9835-cdea8103e25f","Objective","Objective_3","Behaviour",""
"OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","0d9bf653-6318-41ac-b7cf-6b9afdb7ef94","Objective","Objective_4","",""
"OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","537afb5e-9904-47fe-b7fa-34d51e1600bd","Objective","Objective_5","",""
"OBJ6","To assess the treatment response as a function of Apo E genotype.","9a88e668-ef06-4ae6-bf06-10358e369cd8","Objective","Objective_6","",""
